This inventor holds 2 USPTO granted patents and 2 published patent applications and 2 EPO patents. Top assignee: Ucl Business Plc. Active years: 2023-2025.
Company Filing History:
Years Active: 2023-2025
Title: The Innovations of Ben Willcox
Introduction
Ben Willcox is a notable inventor based in Birmingham, GB. He has made significant contributions to the field of biotechnology, particularly in the development of engineered T cell receptors. With a total of 2 patents to his name, Willcox is recognized for his innovative approaches to enhancing T cell functionality.
Latest Patents
Willcox's latest patents focus on engineered T cell receptors (TCRs). The first patent provides an engineered T cell receptor comprising specific amino acid residues that are not present in the corresponding germline TCR amino acid sequence. This innovation aims to improve the efficacy of TCRs in therapeutic applications. The second patent relates to methods for expressing a TCR as an exogenous TCR, selecting TCRs with high cell surface expression, and identifying residues that contribute to the expression level of a TCR. These advancements are crucial for enhancing the performance of T cell therapies.
Career Highlights
Throughout his career, Ben Willcox has worked with various organizations, including UCL Business Plc and UCL Business Ltd. His experience in these companies has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Willcox has collaborated with notable colleagues such as Fiyaz Mohammed and Sharyn Thomas. These partnerships have played a vital role in advancing his research and innovations.
Conclusion
Ben Willcox's contributions to the field of biotechnology, particularly through his patents on engineered T cell receptors, highlight his role as an influential inventor. His work continues to pave the way for advancements in T cell therapies and their applications in medicine.